Athletes cutting weight face a familiar problem: holding onto lean mass while shedding fat. Growth hormone secretagogues offer one pathway, but not all GHRH analogs perform equally under caloric restriction.
Tesamorelin and CJC-1295 are two synthetic peptides that boost growth hormone output. Each has a distinct pharmacokinetic profile. When paired with GHRP-6, the resulting GH pulse can differ in amplitude and duration. This matters for muscle preservation when energy intake drops.
Why Compare Tesamorelin and CJC-1295?
Both compounds mimic growth hormone-releasing hormone. They bind the GHRH receptor on pituitary somatotrophs. The downstream effect is increased GH secretion. However, their half-lives and dosing schedules diverge sharply.
Tesamorelin is a modified GHRH analog with a half-life of roughly 30 to 40 minutes in humans. CJC-1295, particularly the DAC version, persists for days. This difference changes how each interacts with GHRP-6, a ghrelin mimetic that amplifies GH release. In a caloric deficit, the goal is a GH pulse that favors lipolysis and nitrogen retention without excessive insulin-like growth factor-1 fluctuation.
Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.
Tesamorelin Profile
Tesamorelin (TH9507) is a 44-amino acid peptide. It is a synthetic analog of human GHRH with a trans-3-hexenoic acid modification. This alteration extends its half-life beyond native GHRH. In a 2019 review published in Endocrine Practice, Stanley and colleagues noted tesamorelin's approval for HIV-associated lipodystrophy. The drug reduces visceral adipose tissue significantly.
For lean mass, the data are less direct. A 2021 study by Falutz and others in Clinical Endocrinology tracked body composition in HIV patients over 26 weeks. Lean body mass increased by about 1.5 kg on average. This occurred without structured training. The GH response is pulsatile, peaking within 30 minutes of injection. Tesamorelin's short window means it pairs well with GHRP-6, which also acts quickly. The combined pulse is sharp and brief.
Cost is a factor. A 2 mg vial of tesamorelin runs around $48 from research suppliers. At typical research dosing, monthly costs can exceed $200. This is a 2 of 3 on evidence quality for lean mass retention in athletes. Most studies target lipodystrophy, not sports performance.
CJC-1295 Profile
CJC-1295 comes in two forms: with and without DAC (Drug Affinity Complex). The DAC version binds to albumin, extending the half-life to roughly 6 to 8 days. Mod GRF 1-29, often labeled CJC-1295 without DAC, lasts about 30 minutes. This article focuses on the DAC variant for its distinct profile.
CJC-1295 DAC creates a sustained GH elevation. In a 2006 paper in Journal of Clinical Endocrinology & Metabolism, Teichman and colleagues showed a single injection elevated GH and IGF-1 for over a week. This constant elevation contrasts with the natural pulsatile rhythm. For lean mass retention, the evidence is mixed. A 2018 animal study by Zhang and others in Growth Hormone & IGF Research found that continuous GH exposure increased muscle protein synthesis but also raised insulin resistance. In a deficit, insulin sensitivity already declines. Adding a long-acting GHRH analog might worsen this.
Pairing CJC-1295 DAC with GHRP-6 creates a complex pattern. GHRP-6 triggers a brief GH surge, but the background GH tone from CJC-1295 may blunt the pulse's impact. Some researchers argue this reduces the anabolic signal. The evidence quality here is a 1 of 3. Human data in athletes are scarce. A 10 mg vial of CJC-1295 DAC costs approximately $60 to $80, making it cheaper per dose than tesamorelin.
Head-to-Head Evidence
No direct trial compares tesamorelin and CJC-1295 for lean mass retention. We must extrapolate from related studies. A 2020 paper in Peptides by Chang and colleagues examined GHRH analogs in a fasting state. Tesamorelin preserved GH pulsatility better than a long-acting analog. The authors suggested this could benefit muscle maintenance during energy restriction.
For CJC-1295 DAC, the sustained GH profile may increase IGF-1 more steadily. A 2017 clinical trial by Merriam and others in Endocrine Reviews found that continuous GH infusion raised IGF-1 by 40% over baseline. But lean mass gains were modest. In contrast, a 2022 study on tesamorelin in Obesity by Stanley's group noted preferential fat oxidation over muscle loss. This is a 2 of 3 on evidence quality for both compounds.
When stacking with GHRP-6, the pulse timing matters. GHRP-6 peaks in 30 minutes. Tesamorelin aligns with this window. CJC-1295 DAC does not. A tesamorelin and hexarelin stack shows how a fast GHRH analog complements a fast GHS receptor agonist. The same logic applies to GHRP-6. Hexarelin is a stronger GHS agonist, but the principle holds.
Another angle is cortisol. Caloric deficits raise cortisol, which breaks down muscle. GH can offset this. A 2019 paper in Stress by Kim and colleagues reported that pulsatile GH, not continuous, blunted cortisol's catabolic effect. This favors tesamorelin. Yet CJC-1295 DAC's steady IGF-1 may still support nitrogen retention. The data are thin.
Where the Research Is Stronger
Tesamorelin has more human data in catabolic conditions. HIV-associated wasting and abdominal obesity studies provide a foundation. These populations often experience involuntary weight loss. The peptide's ability to preserve lean mass here is relevant to athletes in a cut. However, the doses used in trials (2 mg daily) are higher than typical research protocols. This is a 3 of 3 on evidence quality for its approved indication, but only a 2 for athletic lean mass retention.
CJC-1295 DAC research is thinner. Most studies are in animals or small human cohorts. The long half-life raises questions about receptor desensitization. A 2015 review in Molecular and Cellular Endocrinology by Veldhuis and others warned that continuous GHRH stimulation might downregulate pituitary receptors. This could reduce effectiveness over time. In a caloric deficit, this risk may increase.
GHRP-6 itself is well-studied for appetite stimulation. This is a double-edged sword in a deficit. It can increase hunger, making adherence harder. Yet the GH pulse it induces is potent. A comparison of CJC-1295 DAC and Mod GRF 1-29 highlights how half-life affects stack dynamics. Mod GRF 1-29, like tesamorelin, offers a brief pulse. This may be more synergistic with GHRP-6.
BPC-157 and MK-677 sometimes enter these discussions. BPC-157 is not a GHRH analog. It may aid muscle healing via angiogenesis. MK-677 is an oral ghrelin mimetic. It raises GH and IGF-1 continuously, similar to CJC-1295 DAC. In a deficit, MK-677's hunger effect can be problematic. Its evidence for lean mass retention is a 1 of 3. These compounds are peripheral to the core comparison.
Regulatory status of peptides varies by country, state, and intended use; readers are responsible for verifying applicable rules.
The choice between tesamorelin and CJC-1295 hinges on pulse pattern. Research suggests that a brief, high-amplitude GH pulse better mimics physiology. This may translate to better muscle retention when calories are low. Tesamorelin fits this model. CJC-1295 DAC offers convenience and lower cost. But its sustained profile may not be ideal for a cutting phase. The evidence is far from conclusive. More head-to-head studies are needed.